ACA
UTHR icon

Atlas Capital Advisors’s United Therapeutics UTHR Stock Holding History

Atlas Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-117
Closed -$36.1K – 1000
2025
Q1 		$36.1K Sell
117
-175
-60% -$60K ﹤0.01% 667
2024
Q4 		$103K Sell
292
-5
-2% -$1.84K 0.01% 519
2024
Q3 		$106K Buy
297
+244
+460% +$82.4K 0.02% 486
2024
Q2 		$16.9K Buy
+53
New +$14K ﹤0.01% 702
2023
Q1 		– Sell
-185
Closed -$51.4K – 960
2022
Q4 		$51.4K Buy
+185
New +$46.7K 0.01% 536

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Atlas Capital Advisors's UTHR Position: Q2 2025 in Review

Atlas Capital Advisors sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 117 shares — an estimated $36.1K sold.

Atlas Capital Advisors first reported a position in UTHR in Q4 2022 and held it in 5 quarters. The position peaked at $106K in Q3 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • Atlas Capital Advisors reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Atlas Capital Advisors sold 117 United Therapeutics shares in Q2 2025, an estimated $36.1K.
  • Atlas Capital Advisors first reported a position in United Therapeutics in Q4 2022 and held it in 5 quarters.
  • Atlas Capital Advisors's United Therapeutics position peaked at $106K in Q3 2024.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on Atlas Capital Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.